Your browser doesn't support javascript.
loading
Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
Salphati, Laurent; Chu, Xiaoyan; Chen, Liangfu; Prasad, Bhagwat; Dallas, Shannon; Evers, Raymond; Mamaril-Fishman, Donna; Geier, Ethan G; Kehler, Jonathan; Kunta, Jeevan; Mezler, Mario; Laplanche, Loic; Pang, Jodie; Rode, Anja; Soars, Matthew G; Unadkat, Jashvant D; van Waterschoot, Robert A B; Yabut, Jocelyn; Schinkel, Alfred H; Scheer, Nico.
Afiliação
  • Salphati L; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Chu X; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Chen L; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Prasad B; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Dallas S; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Evers R; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Mamaril-Fishman D; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Geier EG; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Kehler J; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Kunta J; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Mezler M; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Laplanche L; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Pang J; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Rode A; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Soars MG; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Unadkat JD; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • van Waterschoot RA; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Yabut J; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Schinkel AH; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
  • Scheer N; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and
Drug Metab Dispos ; 42(8): 1301-13, 2014 Aug.
Article em En | MEDLINE | ID: mdl-24855184
Organic anion transporting polypeptide (Oatp) 1a/1b knockout and OATP1B1 and -1B3 humanized mouse models are promising tools for studying the roles of these transporters in drug disposition. Detailed characterization of these models will help to better understand their utility for predicting clinical outcomes. To advance this approach, we carried out a comprehensive analysis of these mouse lines by evaluating the compensatory changes in mRNA expression, quantifying the amounts of OATP1B1 and -1B3 protein by liquid chromatography-tandem mass spectrometry, and studying the active uptake in isolated hepatocytes and the pharmacokinetics of some prototypical substrates including statins. Major outcomes from these studies were 1) mostly moderate compensatory changes in only a few genes involved in drug metabolism and disposition, 2) a robust hepatic expression of OATP1B1 and -1B3 proteins in the respective humanized mouse models, and 3) functional activities of the human transporters in hepatocytes isolated from the humanized models with several substrates tested in vitro and with pravastatin in vivo. However, the expression of OATP1B1 and -1B3 in the humanized models did not significantly alter liver or plasma concentrations of rosuvastatin and pitavastatin compared with Oatp1a/1b knockout controls under the conditions used in our studies. Hence, although the humanized OATP1B1 and -1B3 mice showed in vitro and/or in vivo functional activity with some statins, further characterization of these models is required to define their potential use and limitations in the prediction of drug disposition and drug-drug interactions in humans.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Transportadores de Ânions Orgânicos / Transportadores de Ânions Orgânicos Sódio-Independentes Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Transportadores de Ânions Orgânicos / Transportadores de Ânions Orgânicos Sódio-Independentes Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article